ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary BioFirst Corporation received a milestone payment of 10M shares of ForSeeCon Eye Corporations securities to which the parties impute a value of $6 per share based on an internal valuation and a cash payment of $196,000 for its global licensing agreement with ForSeeCon Eye Corporation, which is for the Company's Ophthalmology pipeline, including the medical device Vitargus (valued at $187M, by third-party valuer) (the "Licensed Products").
美股ABVC BioPharma, Inc.（納斯達克：ABVC）宣佈，該公司及其子公司BioFirst Corporation已收到ForSeeCon Eye Corporations證券1000萬股的里程碑支付，根據內部估值，將其價值計入6美元/股，並獲得了196000美元的現金支付。該股權協議爲該公司的眼科醫療產品線提供了全球授權，其中包括經過第三方估價爲1.87億美元的醫療器械Vitargus（“許可產品”）.
ForSeeCon Eye Corporation is a private company registered in the British Virgin Islands. With this payment, the Company has now received aggregate cash payments of $296,000 from ForSeeCon and Oncox ($100,000), one of the Companys other licensees.
ForSeeCon Eye Corporation 是在英屬維爾京群島註冊的私人公司。該公司目前總計已從ForSeeCon和Oncox公司（100,000美元）-該公司的其他許可證持有方，收到了現金支付296,000美元。
In addition to the cash payment, the Company has already received stocks from AiBtl (another licensee) and ForSeeCon, which the company believes are valued at $460M and $60M, respectively. The Company expects to receive additional stocks from OncoX that the Company believes is valued at $50M,3 up to $23.7M in cash and royalties of up to $370M from net sales from all three licensees (AiBtl, ForSeeCon, and OncoX), although such net sales cannot be guaranteed.
除現金支付外，該公司已收到了AiBtl（另一個持有方）和ForSeeCon的股票，公司認爲其價值分別爲4.6億美元和6,000萬美元。該公司預計將從OncoX獲得額外的股票，該公司認爲該股票價值爲5,000萬至等值美元，並且會收到三家持有方（AiBtl，ForSeeCon和OncoX）的淨銷售額折扣-額外的23.7萬美元的現金，以及折扣收入高達3.7億美元的版稅，儘管不能保證這些淨銷售額。
"This milestone payment marks a significant achievement in the partnership between ABVC and ForSeeCon. It reflects ForSeeCon's confidence in the Licensed Products and its determination to bring the Licensed Products to market if it completes the remaining clinical trials. It also underscores the progress towards the overall project objectives," said Dr. Uttam Patil, ABVC's Chief Executive Officer.
"這項里程碑支付標誌着ABVC和ForSeeCon合作關係的重要成就。它反映了ForSeeCon對許可產品的信心，並決心在完成其餘的臨床試驗後將許可產品推向市場。它也強調了向整體項目目標的進展。"ABVC的首席執行官Uttam Patil博士表示。
He added, "The team is thrilled to receive this milestone payment from its valued partner and expects the remaining $6.8M soon. In addition to the milestone payment, the collaboration between ABVC and ForSeeCon will continue to work on adding more sites for the pivotal study and ramp up the momentum for further development to get Vitargus commercialized."
他補充說:"整個團隊都很高興以所鍾愛的合作伙伴獲得這項里程碑支付，並預計很快會收到剩餘的6.8百萬美元。除了里程碑支付外，ABVC和ForSeeCon之間的合作還將繼續努力爲關鍵研究增加更多的現場並增加推動Vitargus商業化的勢頭。"
"It demonstrates the strength of our collaboration and the dedication of both teams to achieving our shared goals. This milestone represents an important step forward in our project and reaffirms our commitment to delivering innovative solutions in the Ophthalmology industry," said Jerry Chang, CEO of ForSeeCon Eye Corporation. He added, "ForSeeCon is also working on getting the Vitargus Pilot plant facility to upgrade and receive the GMP certification."
"這證明了我們團隊之間合作的強度和雙方都爲實現我們共同的目標而努力的決心。"ForSeeCon Eye Corporation的首席執行官Jerry Chang表示。"這個里程碑代表着我們項目向前邁出的重要一步，並重申了我們致力於在眼科醫療行業中提供創新解決方案的承諾。"他補充說:"ForSeeCon Eye Corporation還在努力將Vitargus Pilot工廠設施升級並獲得GMP認證。"
Management believes the Company's product pipeline has excellent market potential. According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, at a CAGR of 7.7%, driven partly by the rising geriatric population worldwide.
管理層認爲，該公司的產品線具有良好的市場潛力。根據iHealthcare Analyst, Inc.的數據，到2029年，視網膜手術設備的全球市場預計將達到43億美元，年複合增長率爲7.7％，部分受全球老齡人口的增長所推動。
ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707
ABVC敦促其股東在公司網站上註冊獲取最新的新聞警報; 請訪問https://abvcpharma.com/?page_id=17707